期刊
ANNUAL REVIEW OF MEDICINE
卷 60, 期 -, 页码 13-23出版社
ANNUAL REVIEWS
DOI: 10.1146/annurev.med.59.110106.212434
关键词
lung vascular development; pulmonary vasoregulation; endothelial cells; smooth muscle cells
资金
- Thrasher Foundation
- National Institutes of Health [HL68702]
Pulmonary arterial hypertension (PAH) is a severe disease with marked morbidity and mortality for which therapeutic strategies have been limited. Basic research in vascular biology has implicated endothelin-1 (ET-1) and its receptors (ETA and ETB) in diverse preclinical models of PAH, and ET-1 has been shown to contribute significantly to PAH in human patients. Despite the complexity of roles of the ET receptors in the development or reversal of PAH in the laboratory, the introduction of endothelin receptor antagonists (ETRAs) to clinical medicine has substantially expanded our therapeutic approach toward severe PAH. This article briefly reviews preclinical data and the current status of ETRAs in the clinical management of PAH.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据